OncBioMune Approved for Trading on OTCQB

BATON ROUGE, LA--(Marketwired - October 02, 2015) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) (the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to announce that the Company's common shares have been approved to commence trading today on the OTCQB® Marketplace of OTC Markets. Listing on the OTCQB platform ensures OncBioMune is meeting all regulatory requirements of the Securities and Exchange Commission (SEC) and listing requirements of OTC Markets to provide greater corporate transparency.

To be eligible for the OTCQB®, companies must meet a minimum bid price, be current in their reporting and undergo an annual verification and management certification process.

"As a new public entity, the upgrade to the OTCQB Marketplace is important as it is part of our long-term plan to increase visibility and liquidity while growing investor confidence," commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune.